Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy

Summary

The primary objective is to evaluate the analgesic efficacy of intravenous (IV) oliceridine administered as needed (PRN) compared with placebo in patients with moderate to severe acute postoperative pain after bunionectomy.

Timeline

Start

2016-05

Primary completion

2016-12

Completion

2017-01

Outcome

Met primary endpoint

release “Results of APOLLO-1 (bunionectomy) All three oliceridine regimens (0.1 mg, 0.35 mg, and 0.5 mg on-demand doses) achieved the primary endpoint” trevena.com ↗

Drugs

Indications

No indication recorded.